A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors
M16-573
Phase 1 other active
Quick answer
A Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors for Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer is a Phase 1 program (other) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie Deutschland GmbH & Co. KG
- Indication
- Patients with relapsed or refractory solid tumors, including: Small cell lung cancer (SCLC); Non-small cell cancer (NSCLC); Breast cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active